“Rise in collaborative efforts between pharmaceutical companies, increase in prevalence of chronic conditions, surge in elderly population, and rise in awareness & preference among populace for oral proteins and peptide-based drugs are the factors that drive the growth of the global oral and peptides market.”
The global oral proteins and peptides market was valued at $643 million in 2016, and is projected to reach $8.23 billion by 2028, growing at a CAGR of 11.7% from 2022 to 2028.
Rise in collaborative efforts between pharmaceutical companies, increase in prevalence of chronic conditions, surge in elderly population, and rise in awareness & preference among population for oral proteins and peptide-based drugs are the factors that drive the growth of the global oral and peptides market. However, high cost associated with drug development and low bioavailability of these drugs restraint the growth to certain extent. On the other hand, rise in novel indications for known oral protein therapeutics, high R&D investment by pharmaceutical companies in oral proteins & peptides drugs, and surge in purchasing power in the emerging markets are expected to provide lucrative opportunities to the market.
Download PDF Report Sample with statistical info @ https://www.alliedmarketresearch.com/request-sample/378
Based on application, gastric & digestive disorders segment contributed the highest revenue in 2016, and is expected to maintain its dominance throughout the forecast period. The approval and high adoption of oral proteins and peptide drugs LINZESS (Allergan, Inc.) and TRULANCE (Synergy Pharmaceuticals, Inc.) the factors that drives the growth of the segment. On the other hand, the diabetes segment is anticipated to grow at the highest CAGR of 13.4% from 2022 to 2028.
Based on region, the U.S. held the lion’s share in terms of revenue during 2016. The high prevalence rate of chronic diseases, surge in adoption of these drugs, and rise in awareness about oral protein and peptide therapeutics are the factors responsible for the growth of the segment. The other segments are expected to grow due to rapid industrialization, increase in disposable income, and rise in government initiatives to modernize healthcare infrastructure.
Key Findings of the Market:
- The insulin drug type segment is expected to register the highest CAGR from 2022 to 2028.
- The gastric & digestive disorder application segment is estimated to contribute the largest share in the oral proteins and peptides market.
- The diabetes segment is anticipated to register the highest growth rate during the forecast period.
- The U.S. contributed the largest share to the oral proteins and peptides market, and is estimated to grow at a CAGR of 11.7%.
For Purchase Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/378
The report provides extensive competitive analysis of key market players, including Proxima Concepts Limited (Diabetology Ltd.), Allergan plc, AstraZeneca plc, Generex Biotechnology Corp., Tarsa Therapeutics Inc., Novo Nordisk A/S, Synergy Pharmaceuticals Inc., Chiasma, Inc., and Biocon Limited.
Scope of The Report
| Report Attribute | Details |
| Market size available for years | 2017-2028 |
| Base year considered | 2018 |
| Forecast period | 2018-2028 |
| Forecast units | Value (USD) |
| Segments covered | Drug Type and Application |
| Geographies covered | North America, Europe, Asia-Pacific, LAMEA |
Related Reports:
Hormonal Contraceptive Market by Product (Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Rings, and Transdermal Patches), Hormone (Progestin-only Contraceptive and Combined Hormonal Contraceptive), Age Group (15-24 Years, 25-34 Years, 35-44 Years, and Above 44 Years), and End User (Hospitals, Household, and Clinics) – Global Opportunity Analysis and Industry Forecast, 2017-2023
Narcolepsy Drugs Market by Disease Type (Daytime Extreme Sleepiness, Cataplexia, and Others) and Therapeutics Type (Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026
Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research
Follow Us on Twitter: https://twitter.com/marketresearcht